Antioxidant transgene in diabetic cardiomyopathy
糖尿病心肌病中的抗氧化转基因
基本信息
- 批准号:7073287
- 负责人:
- 金额:$ 28.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1999
- 资助国家:美国
- 起止时间:1999-08-01 至 2007-12-30
- 项目状态:已结题
- 来源:
- 关键词:NAD(P)H dehydrogenaseantioxidantscatalaseconfocal scanning microscopydiabetes mellitusdiabetic cardiomyopathydisease /disorder modelelectrospray ionization mass spectrometryfree radical oxygenfree radical scavengersgene expressiongenetically modified animalsheart contractionlaboratory mousematrix assisted laser desorption ionizationmetallothioneinmyocardial infarctionwestern blottings
项目摘要
DESCRIPTION (provided by applicant): Many diabetics suffer from severe cardiomyopathy even in the absence of vascular disease. Evidence from animal models and clinical samples implicate reactive oxygen species (ROS) in the development of diabetic cardiomyopathy. Our results confirm the importance of ROS. In the OVE26 model of Type I diabetes we find increased cardiac oxidative damage, increased production of ROS by diabetic cardiomyocytes and protection by antioxidant transgenes. Two different antioxidant proteins targeted to the cardiomyocyte, metallothionein (MT) and catalase prevented most of the primary characteristics of diabetic cardiomyopathy, including reduced contractility, impaired calcium homeostasis and disrupted morphology. Our most recent data implicate mitochondrial electron transport and the enzyme NADPH oxidase in the production of oxidative damage in diabetic cardiomyocytes. This project will identify the cellular source of increased ROS production in diabetic hearts, determine which proteins are the targets of ROS modification and test whether the importance of ROS in Type I diabetes also applies to cardiomyopathy in Type II diabetes. Sources of ROS will be tested by measuring ROS production in diabetic cardiomyocytes as a function of genetic knockout or drug inhibition of potential sources. Breeding diabetic mice to knockout mice for NADPH oxidase will determine if this enzyme is required for the development of diabetic cardiomyopathy. Protein targets of ROS modification in whole heart, mitochondria and sarcoplasmic reticulum will be identified by using proteomic analysis combined with antibodies against oxidatively modified amino acids. To analyze the role of ROS in Type II diabetic cardiomyopathy we will characterize cardiac morphology, ROS production, cardiac function and oxidative damage in the agouti model of Type II diabetes. Agouti mice will be bred to mice protected by cardiac specific antioxidant transgenes to determine if oxidative damage is a requirement for cardiomyopathy in this model.
描述(申请人提供):许多糖尿病患者即使在没有血管疾病的情况下也会患上严重的心肌病。来自动物模型和临床样本的证据表明,活性氧物种(ROS)与糖尿病心肌病的发展有关。我们的结果证实了ROS的重要性。在I型糖尿病的OVE26模型中,我们发现心肌氧化损伤增加,糖尿病心肌细胞产生的ROS增加,并受到抗氧化剂转基因的保护。针对心肌细胞的两种不同的抗氧化蛋白,金属硫蛋白(MT)和过氧化氢酶可预防糖尿病心肌病的大多数主要特征,包括收缩能力降低、钙稳态受损和形态紊乱。我们的最新数据表明,线粒体电子传递和NADPH氧化酶参与了糖尿病心肌细胞氧化损伤的产生。该项目将确定糖尿病心脏中ROS产生增加的细胞来源,确定哪些蛋白质是ROS修饰的目标,并测试ROS在I型糖尿病中的重要性是否也适用于II型糖尿病的心肌病变。ROS的来源将通过测量糖尿病心肌细胞中ROS的产生来测试,这是基因敲除或药物抑制潜在来源的功能。培育糖尿病小鼠以敲除小鼠的NADPH氧化酶将确定这种酶是否是糖尿病心肌病发展所必需的。通过蛋白质组学分析和抗氧化性氨基酸抗体的结合,将确定整个心脏、线粒体和肌浆网中ROS修饰的蛋白质靶点。为了分析ROS在II型糖尿病心肌病中的作用,我们将在II型糖尿病的刺鼠模型上对心脏形态、ROS产生、心功能和氧化损伤进行特征分析。小鼠将被培育成受心脏特异抗氧化剂转基因保护的小鼠,以确定氧化损伤是否是该模型中心肌病的必要条件。
项目成果
期刊论文数量(12)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Overexpression of hexokinase protects hypoxic and diabetic cardiomyocytes by increasing ATP generation.
己糖激酶的过度表达通过增加 ATP 的生成来保护缺氧和糖尿病心肌细胞。
- DOI:10.1385/ct:5:3:293
- 发表时间:2005
- 期刊:
- 影响因子:3.2
- 作者:Ye,Gang;Donthi,RajakumarV;Metreveli,NairaS;Epstein,PaulN
- 通讯作者:Epstein,PaulN
Cardiac phosphatase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase increases glycolysis, hypertrophy, and myocyte resistance to hypoxia.
心脏磷酸酶缺陷的 6-磷酸果糖-2-激酶/果糖-2,6-双磷酸酶会增加糖酵解、肥大和心肌细胞对缺氧的抵抗力。
- DOI:10.1152/ajpheart.91501.2007
- 发表时间:2008
- 期刊:
- 影响因子:0
- 作者:Wang,Qianwen;Donthi,RajakumarV;Wang,Jianxun;Lange,AlexJ;Watson,LewisJ;Jones,StevenP;Epstein,PaulN
- 通讯作者:Epstein,PaulN
Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production.
- DOI:10.2337/diabetes.52.3.777
- 发表时间:2003-03
- 期刊:
- 影响因子:7.7
- 作者:Gang Ye;Naira S. Metreveli;Jun Ren;P. Epstein
- 通讯作者:Gang Ye;Naira S. Metreveli;Jun Ren;P. Epstein
Diabetic Cardiomyopathy in OVE26 Mice Shows Mitochondrial ROS Production and Divergence Between In Vivo and In Vitro Contractility.
OVE26 小鼠的糖尿病心肌病显示线粒体 ROS 产生以及体内和体外收缩性之间的差异。
- DOI:10.1900/rds.2007.4.159
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Song,Ye;Du,Yibo;Prabhu,SumanthD;Epstein,PaulN
- 通讯作者:Epstein,PaulN
Characterization of contractile function in diabetic hypertensive cardiomyopathy in adult rat ventricular myocytes.
- DOI:10.1006/jmcc.2001.1431
- 发表时间:2001-09
- 期刊:
- 影响因子:5
- 作者:L. Wold;D. P. Relling;P. Colligan;G. I. Scott;K. K. Hintz-K.;B. H. Ren;P. Epstein;J. Ren
- 通讯作者:L. Wold;D. P. Relling;P. Colligan;G. I. Scott;K. K. Hintz-K.;B. H. Ren;P. Epstein;J. Ren
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PAUL N EPSTEIN其他文献
PAUL N EPSTEIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PAUL N EPSTEIN', 18)}}的其他基金
Podocytes and oxidative stress in diabetic kidney
糖尿病肾的足细胞和氧化应激
- 批准号:
8013681 - 财政年份:2010
- 资助金额:
$ 28.71万 - 项目类别:
Prolonged Diabetic Damage to Cardiac Mitochondria
长期糖尿病对心脏线粒体的损害
- 批准号:
8004397 - 财政年份:2009
- 资助金额:
$ 28.71万 - 项目类别:
Prolonged Diabetic Damage to Cardiac Mitochondria
长期糖尿病对心脏线粒体的损害
- 批准号:
7027938 - 财政年份:2006
- 资助金额:
$ 28.71万 - 项目类别:
Prolonged Diabetic Damage to Cardiac Mitochondria
长期糖尿病对心脏线粒体的损害
- 批准号:
7564106 - 财政年份:2006
- 资助金额:
$ 28.71万 - 项目类别:
Prolonged Diabetic Damage to Cardiac Mitochondria
长期糖尿病对心脏线粒体的损害
- 批准号:
7334221 - 财政年份:2006
- 资助金额:
$ 28.71万 - 项目类别:
Prolonged Diabetic Damage to Cardiac Mitochondria
长期糖尿病对心脏线粒体的损害
- 批准号:
7166828 - 财政年份:2006
- 资助金额:
$ 28.71万 - 项目类别:
Podocytes and oxidative stress in diabetic kidney
糖尿病肾的足细胞和氧化应激
- 批准号:
6956678 - 财政年份:2005
- 资助金额:
$ 28.71万 - 项目类别:
Podocytes and oxidative stress in diabetic kidney
糖尿病肾的足细胞和氧化应激
- 批准号:
7467297 - 财政年份:2005
- 资助金额:
$ 28.71万 - 项目类别:
相似海外基金
Racial disparities of open angle glaucoma: A study of mitochondria and oxidative stress in human trabecular meshwork
开角型青光眼的种族差异:人类小梁网线粒体和氧化应激的研究
- 批准号:
10735655 - 财政年份:2023
- 资助金额:
$ 28.71万 - 项目类别:
Manganese dioxide as a nanozyme to mitigate oxidative stress in osteoarthritis
二氧化锰作为纳米酶可减轻骨关节炎的氧化应激
- 批准号:
10751638 - 财政年份:2023
- 资助金额:
$ 28.71万 - 项目类别:
Commensal modulation of Peri-implant Microbiome Dysbiosis via Veillonella parvula
小韦荣球菌对种植体周围微生物群失调的共生调节
- 批准号:
10899342 - 财政年份:2023
- 资助金额:
$ 28.71万 - 项目类别:
CT imaging and therapy of inflammatory bowel disease via catalytic ceria nanoparticles
CT 成像和催化二氧化铈纳米粒子治疗炎症性肠病
- 批准号:
10755240 - 财政年份:2022
- 资助金额:
$ 28.71万 - 项目类别:
Arsenic suppresses progesterone receptor signaling and promotes tamoxifen resistance and metastasis of ER+ breast cancer
砷抑制孕激素受体信号传导并促进 ER 乳腺癌的他莫昔芬耐药性和转移
- 批准号:
10662054 - 财政年份:2022
- 资助金额:
$ 28.71万 - 项目类别:
Protecting the kidney and remote organs following renal ischemia
肾缺血后保护肾脏和远端器官
- 批准号:
10369765 - 财政年份:2022
- 资助金额:
$ 28.71万 - 项目类别:
Protecting the kidney and remote organs following renal ischemia
肾缺血后保护肾脏和远端器官
- 批准号:
10609012 - 财政年份:2022
- 资助金额:
$ 28.71万 - 项目类别:
Anti-tumor immunity and intestinal microbiota are modulated by mitochondrial DNA
抗肿瘤免疫和肠道微生物群由线粒体 DNA 调节
- 批准号:
10426606 - 财政年份:2022
- 资助金额:
$ 28.71万 - 项目类别:
Development of Cobinamide as a Novel Treatment for Aortic Aneurysms of Marfan Syndrome: Phase I Pharmacokinetic Studies
Cobinamide 作为马凡综合征主动脉瘤的新型治疗方法的开发:I 期药代动力学研究
- 批准号:
10545967 - 财政年份:2022
- 资助金额:
$ 28.71万 - 项目类别:
Development of anti-inflammatory nanodrug for endometriosis treatment
开发治疗子宫内膜异位症的抗炎纳米药物
- 批准号:
10709492 - 财政年份:2022
- 资助金额:
$ 28.71万 - 项目类别: